The University of Kansas Cancer Center

https://www.kucancercenter.org/

 

2020 ASCO Update on mCRC: Does T-DXd Have Potential in HER2+ Disease Refractory to Standard Therapies?

34 views
September 9, 2020
Comments 0
Login to view comments. Click here to Login